Nearly 1 in 6 Children on GLP-1 Drugs Develop Nutritional Deficiencies

A year into treatment with GLP-1 drugs, nearly one in six children developed nutritional deficiencies—a finding that has begun to reshape how doctors and parents think about prescribing these medications to young people. The drugs, which work by slowing stomach emptying and reducing appetite, have become increasingly common in pediatric medicine as childhood obesity rates climb. But the emergence of this nutritional complication suggests the benefits of weight loss may come with a hidden cost that extends beyond the scale.

GLP-1 medications like semaglutide and tirzepatide were originally developed for adults with type 2 diabetes. Over the past few years, they have been prescribed off-label to children struggling with obesity, often with dramatic results in terms of weight reduction. Parents and doctors have embraced them as a tool against a condition that carries real health risks—cardiovascular disease, type 2 diabetes, joint problems, and psychological distress. The drugs work, and for many families, they have felt like a breakthrough. But the nutritional deficiency finding complicates that picture considerably.

The specific rate—approximately 17 percent of children on these medications within twelve months—emerged from research that has prompted pediatricians and public health officials to reconsider how these drugs should be deployed in younger populations. A child's body is not a small adult's body. Growth and development depend on consistent, adequate nutrition. Deficiencies in key vitamins and minerals during childhood can have lasting consequences: weakened bones, impaired cognitive development, compromised immune function, and stunted growth. The concern is not merely theoretical. These are children whose bodies are still building themselves.

The mechanism appears straightforward. GLP-1 drugs suppress appetite and slow gastric emptying, which means children eat less and absorb nutrients differently. When caloric intake drops sharply, the body may not receive enough of certain micronutrients—iron, vitamin B12, calcium, and others—even if the food that is eaten is nutritionally dense. The appetite suppression is so effective that some children simply do not feel hungry enough to eat adequately varied diets. Parents report that their children lose interest in food altogether, making it difficult to ensure they consume the nutrients they need.

The finding has raised urgent questions about medical oversight. Are children on these drugs being monitored closely enough? Are they receiving nutritional counseling? Are doctors checking blood work regularly to catch deficiencies early? The answers, so far, appear inconsistent. Some pediatricians are implementing rigorous monitoring protocols—regular lab work, dietary assessments, supplementation when needed. Others are prescribing the drugs with minimal follow-up, leaving families to navigate the complications on their own. The gap between best practice and actual practice is significant.

Parents face a genuine dilemma. Childhood obesity is a serious condition with serious consequences. A child who loses weight on a GLP-1 drug may experience immediate improvements in mobility, confidence, and health markers like blood pressure and blood sugar. But that same child may be developing a nutritional deficit that will not become apparent for months or years. The choice is not between perfect health and imperfect health; it is between different kinds of risk, and the long-term calculus remains uncertain.

What comes next is likely to be a period of recalibration. Medical organizations are beginning to issue guidance on pediatric GLP-1 use, emphasizing the need for careful patient selection, close monitoring, and nutritional support. Some experts are calling for these drugs to be reserved for children with the most severe obesity and related health complications, rather than prescribed more broadly. Others are advocating for mandatory nutritional counseling and supplementation protocols as a condition of use. The conversation is shifting from whether these drugs work to whether they should be used, and under what circumstances, and with what safeguards in place.